Table 2 Incidence rate and multivariate-adjusted rate ratio of HBsAg seroclearance by HLA variants and HBV genotypes.
Variant genotype | No. of participants (%) | Case No. /Person-years of follow-up | Incidence rate (per 1000/yr) | Crude rate ratio (95% confidence interval) | P valueb | Adjusted rate ratio (95% confidence interval)a | P valueb |
|---|---|---|---|---|---|---|---|
rs1710 (HLA-G) C > G | |||||||
Genotype B (n = 1189) | |||||||
CC | 431 (36) | 51 /3361 | 15.17 | 1.00 (Referent) | 1.00 (Referent) | ||
GC | 550 (46) | 54 /4658 | 11.59 | 0.75 (0.51–1.10) | 0.135 | 0.63 (0.42–0.92) | 0.018 |
GG | 208 (17) | 21 /1617 | 12.98 | 0.86 (0.52–1.42) | 0.547 | 0.73 (0.44–1.23) | 0.236 |
Additive model | 0.88 (0.68–1.14) | 0.338 | 0.80 (0.61–1.04) | 0.095 | |||
Genotype C (n = 542) | |||||||
CC | 202 (37) | 38 /1827 | 20.79 | 1.00 (Referent) | 1.00 (Referent) | ||
GC | 264 (49) | 50 /2355 | 21.23 | 1.01 (0.66–1.54) | 0.982 | 1.09 (0.71–1.69) | 0.691 |
GG | 76 (14) | 25 /670 | 37.34 | 1.98 (1.20–3.29) | 0.008 | 2.13 (1.27–3.56) | 0.004 |
Additive model | 1.36 (1.03 1.78) | 0.028 | 1.42 (1.08–1.86) | 0.012 | |||
rs2770 (HLA-B) A > G | |||||||
Genotype B (n = 1139) | |||||||
AA | 539 (47) | 62 /4300 | 14.42 | 1.00 (Referent) | 1.00 (Referent) | ||
AG | 476 (42) | 48 /3874 | 12.39 | 0.84 (0.58–1.23) | 0.375 | 0.76 (0.51–1.11) | 0.156 |
GG | 124 (11) | 8 /1061 | 7.54 | 0.49 (0.24–1.03) | 0.061 | 0.40 (0.19–0.85) | 0.017 |
Additive model | 0.76 (0.58–1.01) | 0.060 | 0.69 (0.51- 0.92) | 0.011 | |||
Genotype C (n = 518) | |||||||
AA | 228 (44) | 52 /2023 | 25.7 | 1.00 (Referent) | 1.00 (Referent) | ||
AG | 230 (44) | 43 /2111 | 20.37 | 0.75 (0.50–1.13) | 0.166 | 0.82 (0.54–1.26) | 0.366 |
GG | 60 (12) | 11 /545 | 20.18 | 0.71 (0.37–1.37) | 0.305 | 0.74 (0.38–1.44) | 0.377 |
Additive model | 0.81 (0.60–1.08) | 0.154 | 0.85 (0.63–1.14) | 0.280 | |||
